Tau protein as a therapeutic target in Alzheimer’s disease and other neurodegenerative disorders

Bibliography

• ALZHEIMER A: über eine eigenartige Erkrankung der Hirnrinde. Allgemeine Zeitschrift fur Psychaitrie und Psychisch-Gerichtlich Medizine (1907) 64:146-148. [Transla-tions: WILKINS RH, BRODIE IA: Alzheimer's disease. Arch. Neurol (1969) 21:109-110; JARVIK L, GREENSON H: About a peculiar disease of the cerebral cortex. Alz. Dis. Assoc. Disord. (1987) 1:7–8.]
   Google Scholar
• PERUSINI G: Sul valore nosografico di alcuni reperti istopatologici caratteristiche per la senita. Rivisita Italiana di Neuropatologia, Psichiatria ed Elettroterapia (1911) 4:193–213.
   Google Scholar
• BLOCQ P, MARINESCO G: Sur les lesions et lapathogenie de l'epilepsie dite essentielle. Semaine Medicale (1892) 12:445–446.
   Google Scholar
• BRAAK H, BRAAK E, GRUNDKE-IQBAL I, IQBAL K:Occurrence of neuropil threads in the senile human brain and in Alzheimer's disease: a third location of paired helical filaments outside the neurofibrillary tangles and neuritic plaques. NeuroscL Lett. (1986) 65:351–355.
   PubMed Web of Science ®Google Scholar
• LARNER AJ: The cortical neuritic dystrophy ofAlzheimer's disease: nature, significance and possible pathogenesis. Dementia (1995) 6:218–224.
   PubMedGoogle Scholar
• KIDD M: Paired helical filaments in electron micros-copy of Alzheimer's disease. Nature (1963) 197:192–193.
   PubMed Web of Science ®Google Scholar
• TERRY RD: The fine structure of neurofibrillary tangles in Alzheimer's disease. J. Neuropathol. Exp. Neurol. (1963) 22:629–641.
   PubMed Web of Science ®Google Scholar
• CROWTHER RA: Straight and paired helical filaments in Alzhemier's disease have a common structural unit. Proc. Natl. Acad. Sci. USA (1991) 88:2288–2292.
   PubMed Web of Science ®Google Scholar
• WEINGARTEN MD, LOCKWOOD AH, HWO S-H,KIRSCHNER MW: A protein factor essential for microtu-bule assembly. Proc. NatI Acad. Sci. USA (1975) 72:1858–1862.
   PubMed Web of Science ®Google Scholar
• CLEVELAND CB, SYGOWSKI LA, SCOTT CW, SOBEL El:Purification of tau, a microtubule associated protein that induces assembly of microtubules from purified tubulin. j Mol Biol. (1977) 116:207–225.
   PubMed Web of Science ®Google Scholar
• WISCHIK CM, NOVAK M, THOGERSEN HC eta].: Isolationof a fragment of tau derived from the core of the paired helical filament of Alzheimer's disease. Proc. Natl. Acad. ScL USA (1988) 85:4506–4510.
   Google Scholar
• BRAAK H, BRAAK E: Neuropathological stageing [sic] ofAlzheimer-related changes. Acta Neuropathol. (1991) 82:239–259.
   PubMed Web of Science ®Google Scholar
• DELACOURTE A, DAVID JP, SERGEANT N et al.: Thebiochemical pathway of neurofibrillary degeneration in aging and Alzheimer's disease. Neurology (1999) 52:1158–1165.
   PubMed Web of Science ®Google Scholar
• LARNER AJ: The cerebellum in Alzheimer's disease: a review. Dement. Ger. Cog. Disord. (1997) 8:203–209.
   PubMedGoogle Scholar
• MCKEE AC, KOSIK KS, KOWALL NW: Neuritic pathology and dementia in Alzheimer's disease. Ann. Neurol. (1991) 30:156–165.
   PubMed Web of Science ®Google Scholar
• ARRIAGADA PV, GROWDON JH, HEDLEY WHITE ET, HYMAN BT: Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. Neurology (1992) 42:631–639.
   PubMed Web of Science ®Google Scholar
• GOEDERT M: Tau protein and the neurofibrillary pathology of Alzheimer's disease. Trends Neurosci. (1993) 16:460–465.
   PubMed Web of Science ®Google Scholar
• YEN S-H, NACHARAJU P, KO L-W, KENESSEY A, LIU W-K: Microtubule-associated protein tau: biochemical modifications, degradation and Alzheimer's disease. In: Handbook of theAging Brain. Wang E, Snyder DS (Eds.), Academic Press, San Diego, USA (1998):153–169.
   Google Scholar
• GOEDERT M, TROJANOWSKI JQ, LEE VM-Y: T protein and the neurofibrillary pathology of Alzheimer's disease. In: Molecular Mechanisms of Dementia. Wasco W, Tanzi RE (Eds.), Humana, Totawa, NJ, USA (1997):199–218.
   Google Scholar
• CLARK CM, EWBANK D, LEE VM-Y, TROJANOWSKI JQ: Molecular pathology of Alzheimer's disease: neuronal cytoskeletal abnormalities. In: The Dementias. Growdon JH, Rossor MN (Eds.), Butterworth Heinemann, Boston, USA (1998):285–304.
   Google Scholar
• WISCHIK CM, LAI R, HARRINGTON CR et al.: Structure, biochemistry and molecular pathogenesis of paired helical filaments in Alzheimer's disease. In: Pathobi-ology of Alzheimer's Disease. Goate AM, Ashall F (Eds.), Academic Press, London, UK (1995):9–39.
   Google Scholar
• WISCHIK CM, EDWARDS PC, HARRINGTON CR: The tau protein amyloidosis of Alzheimer's disease: its mechanisms, potential trigger factors and consequences. In: Neurobiology of Alzheimer's Disease. Dawbarn D, Allen SJ (Eds.), Pios Scientific Publishers, Oxford, UK (1995):89–148.
   Google Scholar
• DELACOURTE A, SERGEANT N, WATTEZ A, ROBITAILLE Y: The biochemistry of the cytoskeleton in Pick complex. In: Pick's Disease and Pick Complex. Kertesz A, Munoz DG (Eds.), Wiley-Liss, Inc., New York, USA (1998):243–258.
   Google Scholar
• SPILLANTINI MG, GOEDERT M: Tau protein pathology in neurodegenerative disease. Trends NeuroscL (1998) 21:428–433.
   PubMed Web of Science ®Google Scholar
• YAMADA KM, SPOONER BS, WESSELLS NK: Axon growth: roles of microfilaments and microtubules. Proc. Natl. Acad. ScL USA (1970) 66:1206–1212.
   PubMed Web of Science ®Google Scholar
• CACERES A, KOSIK KS: Inhibition of neurite polarity by tau antisense oligonucleotides in primary cerebellar neurons. Nature (1990) 343:461–463.
   PubMed Web of Science ®Google Scholar
• HARADA A, OGUCHI K, OGABE S et al.: Altered microtu-bule organization in small-calibre axons of mice lacking tau protein. Nature (1994) 369:488–491.
   PubMed Web of Science ®Google Scholar
• GOEDERT M, JAKES R, CROWTHER RA et al.: The abnormal phosphorylation of tau protein at Ser-202 in Alzheimer's disease recapitulates phosphorylation during development. Proc. Natl. Acad. ScL USA (1993) 90:5066–5070.
   PubMedGoogle Scholar
• BRAAK E, BRAAK H, MANDELKOW EM: A sequence of cytoskeleton changes related to the formation of neurofibrillary tangles and neuropil threads. Acta Neuropathol. (1994) 87:554–567.
   PubMed Web of Science ®Google Scholar
• LOVESTONE S, REYNOLDS CH, LATIMER D et al.: Alzheimer's disease-like phosphorylation of the microtubule-associated protein tau by glycogen synthase kinase-3 in transfected mammalian cells. Curr. Biol. (1994) 4:1077–1086.
   PubMedGoogle Scholar
• •See note for reference 31.
   Google Scholar
• BROWNLEES J, IRVING NG, BRION JP et al.: Tau phospho- rylation in transgenic mice expressing glycogen synthase kinase 36 transgenes. NeuroReport (1997) 8:3251–3255.
   PubMed Web of Science ®Google Scholar
• •Two papers demonstrating that GSK-313 phosphorylates tau protein in vivo.
   Google Scholar
• HONG M, CHEN DRC, KLEIN PS, LEE VM-Y: Lithium reduces tau phosphorylation by inhibition of glycogen synthase kinase-3. J. Biol. Chem. (1997) 272:25326–25332.
   PubMed Web of Science ®Google Scholar
• •See note for reference 33.
   Google Scholar
• MUNOZ-MONTANO JR, MORENO FJ, AVILA J, DIAZ-NIDO J: Lithium inhibits Alzheimer's disease-like tau protein phosphorylation in neurons. FEBS Lett. (1997) 411:183–188.
   PubMed Web of Science ®Google Scholar
• •Two papers demonstrating that inhibition of GSK-313 by lithium inhibits tau phosphorylation.
   Google Scholar
• TAKASHIMA A, MURAYAMA M, MURAYAMA O, HONDA T, TOMITA T, IWATSUBO T: Association of presenilin 1 with glycogen synthase kinase-36 and its substrate tau. In: Alzheimer's Disease: Etiology, Pathogenesis and Therapeutics. Iqbal K, Swaab DF, Winblad B, Wisniewski HM (Eds.), Wiley, Chichester, UK (1999):323–331.
   Google Scholar
• HAASS C: Presenilins: genes for life or death. Neuron (1997) 18:687–690.
   PubMed Web of Science ®Google Scholar
• WANG J-Z, GRUNDKE-IQBAL I, IQBAL K: Protein kinase-A and glycogen synthase kinase-3 in combina-tion hyperphosphorylate tau to an Alzheimer's disease-like state. In: Alzheimer's Disease: Etiology, Pathogenesis and Therapeutics. Iqbal K, Swaab DF, Winblad B, Wisniewski HM (Eds.), Wiley, Chichester, UK (1999):311–321.
   Google Scholar
• IQBAL K, ALONSO ADC, GONG C-X et al.: Alzheimer neurofibrillary degeneration: a feasible and key target for therapeutics. In: Alzheimer's Disease: from Molecular Biology to Therapy. Becker R, Giacobini E (Eds.), Birkhauser, Boston, USA (1996):31–36.
   Google Scholar
• ARENDT T, HOLZER M, FRUTH R, BRÜCKNER MK, GARTNER A: Paired helical filament-like phosphoryla-tion of tau, deposition of p/A4-amyloid and memory impairment in rat induced by chronic inhibition of phosphatase 1 and 2A. Neuroscience (1995) 69:691–698.
   PubMed Web of Science ®Google Scholar
• BRAMBLETT GT, GOEDERT M, JAKES R, MERRICK SE, TROJANOWSKI JQ, LEE VM-Y: Abnormal tau phospho-rylation at Ser396 in Alzheimer's disease recapitulates development and contributes to reduced microtubule bundling. Neuron (1993) 10:1089–1099.
   PubMed Web of Science ®Google Scholar
• BIERNAT J, GUSTKE N, DREWES G, MANDELKOW E-M, MANDELKOW E: Phosphorylation of Ser262 strongly reduces binding of tau to microtubules: distinction between PHF-like immunoreactivity and microtubule binding. Neuron (1993) 11:153–163.
   PubMed Web of Science ®Google Scholar
• STRITTMATTER WJ, WEISGRABER KH, GOEDERT M et al: Hypothesis: microtubule instability and paired helical filament formation in the Alzheimer's disease brain are related to apolipoprotein E genotype. Exp. Neurol. (1994) 125:63–171.
   Google Scholar
• SAUNDERS AM, STRITTMATTER WJ, SCHMECHEL D et al:Association of apolipoprotein E allele 64 with late-onset familial and sporadic Alzheimer's disease. Neurology (1993) 43:1467–1472.
   PubMed Web of Science ®Google Scholar
• CROWTHER RA, OLESEN OF, SMITH MJ, JAKES R, GOEDERT M: Assembly of Alzheimer-like filaments from full-length tau protein. FEBS Lett. (1994) 337:135–138.
   PubMed Web of Science ®Google Scholar
• GOEDERT M, JAKES R, SPILLANTINI MG, HASEGAWA M,SMITH MJ, CROWTHER RA: Assembly of microtubule-associated protein tau into Alzheimer-like filaments induced by sulphated glycosaminoglycans. Nature (1996) 383:550–553.
   PubMed Web of Science ®Google Scholar
• MUKAETOVA-LADINSKA EB, HARRINGTON CR, ROTH M,WISCHIK CM: Biochemical and anatomical redistribu-tion of tau protein in Alzheimer's disease. Am. J. Pathol. (1993) 143:565–578.
   PubMed Web of Science ®Google Scholar
• NOVAK M, UGOLINI G, FASULO L, VISINTIN M, OVECKA M, CATTANEO A: Truncation of tau and neurodegenera-tion. In: Alzheimer's Disease: Etiology, Pathogenesis and Therapeutics. Iqbal K, Swaab DF, Winblad B, Wisniewski HM (Eds.), Wiley, Chichester, UK (1999):281–291.
   Google Scholar
• FOX N, HARVEY RJ, ROSSOR MN: Protein folding, nucleation phenomena and delayed neurodegenera-tion in Alzheimer's disease. Rev. Neurosci. (1996) 7:21–28.
   PubMedGoogle Scholar
• BUEE-SCHERRER V, BUEE L, HOF PR et al: Tau variants in aging and neurodegenerative disorders. In: Alzheimer's Disease: Lessons from Cell Biology. Kosik KS, Christen Y, Selkoe DJ (Eds.), Springer, Berlin, Germany (1995):132–149.
   Google Scholar
• HARDY J, ALLSOP D: Amyloid deposition as the central event in the aetiology of Alzheimer's disease. Trends Pharmacol. Sci. (1991) 12:383–388.
   PubMed Web of Science ®Google Scholar
• SCHEUNER D, ECKMAN C, JENSEN M et al. Secreted amyloid 13-protein similar to that in the amyloid plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nature Merl. (1996) 2:864–870.
   PubMed Web of Science ®Google Scholar
• VICKERS JC: A cellular mechanism for the neuronal changes underlying Alzheimer's disease. Neuroscience (1997) 78:629–639.
   PubMed Web of Science ®Google Scholar
• LARNER AJ: Neurite growth-inhibitory properties of amyloid -peptides in vitro: A1325-35, but not AI31-40, is inhibitory. Neurosci. Res. Commun. (1997) 20:147–155.
   Google Scholar
• BUSCIGLIO J, LORENZO A, YEH J, YANKNER BA: p-amyloid fibrils induce tau phosphorylation and loss of microtubule binding. Neuron (1995) 14:879–888.
   PubMed Web of Science ®Google Scholar
• TERRY RD: The pathogenesis of Alzheimer's disease: an alternative to the amyloid hypothesis. J. Neuropathol Exp. Neurol. (1996) 55:1023–1025.
   PubMed Web of Science ®Google Scholar
• LARNER AJ: The pathogenesis of Alzheimer's disease: an alternative to the amyloid hypothesis. J. Neuropa-thol. Exp. Neurol. (1997) 56:214–215.
   PubMedGoogle Scholar
• POORKAJ P, BIRD TD, WIJSMAN E et al.: Tau is a candidate gene for chromosome 17 frontotemporal dementia. Ann. Neurol. (1998) 43:815–825.
   PubMed Web of Science ®Google Scholar
• •The first three reports of mutations in the tau gene causing frontotemporal dementia and multiple system tauopathy.
   Google Scholar
• HUTTON M, LENDON CL, RIZZU P et al.: Association of missense and 5'-splice site mutations in tau with the inherited dementia FTDP-17. Nature (1998) 393:702–705.
   PubMed Web of Science ®Google Scholar
• •See note for reference 56.
   Google Scholar
• SPILLANTINI MG, MURRELL JR, GOEDERT M et al.: Mutation in the tau gene in familial multiple system tauopathy with presenile dementia. Proc. Natl. Acad. Sci. USA (1998) 95:7737–7741.
   PubMed Web of Science ®Google Scholar
• •See note for reference 56.
   Google Scholar
• MORRIS HR, PEREZ-TUR J, JANSSEN JC et al.: Mutation in the tau exon 10 splice site region in familial fronto-temporal dementia. Ann. Neurol (1999) 45:270–271.
   PubMedGoogle Scholar
• GOEDET M, SPILLANTINI MG, CROWTHER RA et al.: Tau gene mutation in familial progressive subcortical gliosis. Nature Med. (1999) 5:454–457.
   PubMedGoogle Scholar
• HARDY J, DUFF K, HARDY KG, PEREZ-TUR J, HUTTON M: Genetic dissection of Alzheimer's disease and related dementias: amyloid and its relationship to tau. Nature Neurosci. (1998) 1:355–358.
   PubMed Web of Science ®Google Scholar
• ARRASATE M, PEREZ M, ARMAS-PORTELA R, AVILA J: Polymerization of tau peptides into fibrillar structures: the effect of FTDP-17 mutations. FEBS Lett. (1999) 446:199–202.
   PubMedGoogle Scholar
• •Three studies showing that tau gene missense mutations disrupt microtubule function and cellular organisation.
   Google Scholar
• NACHARAJU P, LEWIS J, EASSON C et al.: Accelerated filament formation from tau protein with specific FTDP-17 missense mutations. FEBS Lett. (1999) 447:195–199.
   Google Scholar
• •See note for reference 62.
   Google Scholar
• ARAWAKA S, USAMI M, SAHARA N, SCHELLENBERG GD, LEE G, MORI H: The tau mutation (val337mefi disrupts cytoskeletal networks of microtubules. Neuroreport (1999) 10:993–997.
   PubMedGoogle Scholar
• •See note for reference 62.
   Google Scholar
• GONG C-X, SINGH TJ, GRUNDKE-IQBAL I, IQBAL K: Alzheimer's disease abnormally phosphorylated T is dephosphorylated by protein phosphatase-2B (calcineuria j Neurochem. (1994) 62:803-806.
   Google Scholar
• LARNER AJ, ROSSOR MN: Alzheimer's disease: towards therapeutic manipulation of the amyloid precursor protein and amyloid -peptides. Exp. Opin. Ther. Patents (1997) 7(10):1115–1127.
   Web of Science ®Google Scholar
• PROUT KA, LARNER AJ: Emerging therapeutic possibili-ties in prion diseases: patents 1993-1998. Exp. Opin. Ther. Patents (1998) 8(10):1099–1108.
   Google Scholar
• MANSFIELD SG, GORDON-WEEKS PR: Dynamic post-translational modification of tubulin in rat cerebral cortical neurons extending neurites in culture: effects of taxol. j Neurocytol (1991) 20:654–666.
   PubMedGoogle Scholar
• GAMES D, ADAMS D, ALESSANDRINI R eta].: Alzheimer-type neuropathology in transgenic mice overex-pressing V717F 13-amyloid precursor protein. Nature (1995) 373:523–527.
   Google Scholar
• Transgenic animal model for Alzheimer's disease. Exp. Opin. Ther. Patents (1998) 8(6):729–732.
   Google Scholar
• Transgenic animals and cell lines for screening drugs effective for the treatment or prevention of Alzheimer's disease. Exp. Opin. Ther. Patents (1999) 9(2)201–204.
   Google Scholar
• LARNER AJ: Hypothesis: physiological and pathological interrelationships of amyloid 13 peptide and the amyloid precursor protein. BioEssays (1995) 17:819–824.
   PubMed Web of Science ®Google Scholar
• CAUGHEY B, CHESEBRO B: Prion protein and the transmissible spongiform encephalopathies. Trends Cell Biol. (1997) 7:56–62.
   PubMed Web of Science ®Google Scholar
• SPILLANTINI MG, CROWTHER RA, JAKES R, HASEGAWA M, GOEDERT M: a-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with Lewy bodies. Proc. Natl. Acad. ScL USA (1998) 95:6469–6473.
   PubMed Web of Science ®Google Scholar
• DIFIGLIA M, SAPP E, CHASE KO et al: Aggregation ofhuntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science (1997) 277:1990–1993.
   PubMed Web of Science ®Google Scholar
• PAULSON HL, PEREZ MK, TROTTIER Y et al.: Intranuclearinclusions of expanded polyglutamine protein in spinocerebellar ataxia Type 3. Neuron (1997) 19:333–344.
   PubMed Web of Science ®Google Scholar
• VIDAL R, FRANGIONE B, ROSTAGNO A et al.: A stop-codon mutation in the BR/gene associated with familial British dementia. Nature (1999) 399:776–781.
   PubMed Web of Science ®Google Scholar
• SARGOVI HU, BURGESS K: Small molecule and protein-based neurotrophic ligands: agonists and antagonists as therapeutic agents. Exp. Opin. Ther. Patents (1999) 9 (6) :737–751.
   Google Scholar
• LU P-J, WULF G, ZHOU XZ, DAVIES P, LU KP: The prolyl isomerase Pinl restores the function of Alzheimer- associated phosphorylated tau protein. Nature (1999) 399:784–788.
   PubMedGoogle Scholar